2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 122

Poor Prognostic Factors at the Start of Methotrexate Therapy Are Not Associated with Worse Treatment Response: Results from the Rheumatoid Arthritis Medication Study
Abstract Number: 2061

Population-Specific Factors Associated with Fractional Excretion of Uric Acid
Abstract Number: 702

Positive Direct Coombs’ Test in the Absence of Hemolytic Anemia Predicts High Disease Activity and Poor Renal Response in Systemic Lupus Erythematosus
Abstract Number: 11

Possible Therapeutics for Antiphospholipid Antibody Related Thrombocytopenia: A Systemic Review and Meta-Analysis
Abstract Number: 431

Post-Marketing Surveillance of Tofacitinib in Japanese Patients with Rheumatoid Arthritis: An Interim Report of Safety Data
Abstract Number: 1228

Postmenopausal Breast Cancer Patients on Aromatase Inhibitor Therapy and Their Increased Risk of Fragility Fracture
Abstract Number: 2025

Potential Clinical Utility of Manu-Scan, the Novel Optical Molecular Imaging, in Patients with Hand Rheumatoid Arthritis
Abstract Number: 2501

Potential Differences in Axial Spondyloarthritis Disease Activity Categorization Using Different Minimum Values for High-Sensitivity CRP in Ankylosing Spondylitis Disease Activity Score Calculation and Different Definitions of Disease Flare
Abstract Number: 238

Power Dopper Ultrasonography Detects Superior Efficacy of Non-TNF Biologics Compared to Cycling of TNF Inhibitors in RA Patients Inadequate Response to First TNF Inhibitors
Abstract Number: 2041

Practice Improvement Utilizing Six Sigma and Health Informatics in an Academic Setting
Abstract Number: 2839

Practice Patterns of Pneumocystis Pneumonia Prophylaxis in Connective Tissue Diseases: a Survey of Infectious Disease Physicians
Abstract Number: 790

Pre-Clinical Evidences of Immunomodulatory Activities of Tuftsin-Phosphorylcholine on Samples from Patients with Giant Cell Arteritis in Comparison to Corticosteroids
Abstract Number: 2881

Pre-Existing Psoriasis Is Predictive for Clinical Relapse after Drug-Free Remission Induced By Therapy with Golimumab in Early Peripheral Spondyloarthritis
Abstract Number: 2027

Pre-Visit Planning Improves Pneumococcal Vaccination in Patients with Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 175

Precisely Controlled Differential Gene Expression System to Investigate the Effect of eQTL

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].